Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Biohaven Ltd. regarding a class action lawsuit due to alleged misleading statements about the company's product candidates and their regulatory prospects [1][2]. Group 1: Allegations - The complaint alleges that during the class period from March 24, 2023, to May 14, 2025, Biohaven's statements regarding the regulatory prospects of its product candidate, troriluzole, were overstated [1]. - It is claimed that the efficacy and clinical prospects of BHV-7000 as a treatment for bipolar disorder were also overstated [1]. - The revelations of these issues are likely to have a significant negative impact on Biohaven's business and financial condition [1]. Group 2: Class Action Details - Shareholders who purchased shares of BHVN during the specified class period are encouraged to register for the class action, with a deadline of September 12, 2025, to seek lead plaintiff status [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Biohaven Ltd. due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's drug candidates and their regulatory prospects [3][5]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses exceeding $50,000 in Biohaven between March 24, 2023, and May 14, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Biohaven, with a deadline of September 12, 2025, for investors to seek the role of lead plaintiff [3]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [7]. Group 2: Allegations Against Biohaven - The complaint alleges that Biohaven and its executives made false and misleading statements regarding the regulatory prospects of the drug troriluzole for treating spinocerebellar ataxia (SCA) and the efficacy of BHV-7000 for bipolar disorder [5]. - It is claimed that the overstated regulatory prospects and clinical data, once revealed, would significantly negatively impact Biohaven's business and financial condition [5]. - Following a press release on May 14, 2025, regarding an extension of the PDUFA date for troriluzole, Biohaven's stock price fell by $3.84 per share, or 19.53%, closing at $15.82 per share [6]. Group 3: Firm Background and Contact Information - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. - The firm encourages anyone with information regarding Biohaven's conduct, including whistleblowers and former employees, to contact them [8].

Core Viewpoint - A class action securities lawsuit has been filed against Biohaven Ltd. alleging securities fraud that negatively impacted investors between March 24, 2023, and May 14, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Biohaven Ltd. made false statements regarding the regulatory prospects of its product candidate, troriluzole, and the efficacy of BHV-7000 for bipolar disorder, overstating their potential [2]. - It is alleged that the revelations of these misstatements would likely have a significant negative impact on Biohaven's business and financial condition [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until September 12, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, highlighting its expertise in complex securities litigation [4].

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. ("Biohaven Ltd." or the "Company") (NYSE: BHVN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Biohaven Ltd. investors who were adversely affected by alleged securities fraud between March 24, 2023 and May 14, 2025. Follow the link below to get more information and be contacted by a member of our team: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Ko ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Biohaven Ltd. regarding a class action lawsuit due to alleged misleading statements about the company's product candidates and their regulatory prospects [1][2]. Summary by Sections Allegations - The complaint alleges that during the class period from March 24, 2023, to May 14, 2025, Biohaven's defendants made materially false and misleading statements regarding: - The regulatory prospects of the product candidate, troriluzole, for treating SCA were overstated [1]. - The efficacy and clinical prospects of BHV-7000 for bipolar disorder were also overstated [1]. - The revelation of these issues is likely to significantly negatively impact Biohaven's business and financial condition [1]. - Consequently, the public statements made by the defendants were materially false and misleading throughout the relevant period [1]. Next Steps for Shareholders - Shareholders who purchased shares of BHVN during the specified timeframe are encouraged to register for the class action by September 12, 2025 [2]. - Registration allows shareholders to be enrolled in a portfolio monitoring software for status updates throughout the case lifecycle [2]. Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights who have suffered from deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflated stock prices [3].

Core Viewpoint - A class action securities lawsuit has been filed against Biohaven Ltd. alleging securities fraud that negatively impacted investors between March 24, 2023, and May 14, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Biohaven Ltd. made false statements regarding the regulatory prospects of its product candidate, troriluzole, and overstated the efficacy of BHV-7000 for treating bipolar disorder [2]. - It is alleged that the misleading statements had a significant negative impact on Biohaven's business and financial condition once the truth was revealed [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 12, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action securities lawsuit has been filed against Biohaven Ltd. due to alleged securities fraud affecting investors between March 24, 2023, and May 14, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Biohaven Ltd. made false statements regarding the regulatory prospects of its product candidate, troriluzole, and the efficacy of BHV-7000 for bipolar disorder, which were overstated [2]. - The complaint suggests that the revelation of these misstatements is likely to have a significant negative impact on Biohaven's business and financial condition [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until September 12, 2025, to request to be appointed as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - Investors in Biohaven Ltd. have the opportunity to lead a securities fraud class action lawsuit due to alleged misrepresentations regarding the company's drug candidates and their regulatory prospects [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that from March 24, 2023, to May 14, 2025, Biohaven's management failed to disclose critical information about the regulatory prospects of its drug, troriluzole, for treating SCA, and the sufficiency of the data submitted for its approval [2] - It is claimed that the efficacy and clinical prospects of another drug, BHV-7000, for treating bipolar disorder were also overstated [2] - The lawsuit suggests that the eventual revelation of these issues would significantly negatively impact Biohaven's business and financial condition [2] - Defendants' positive statements regarding the company's operations and prospects were allegedly materially misleading and lacked a reasonable basis [2]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Biohaven Ltd. regarding a class action lawsuit due to alleged misleading statements about the company's product candidates and their regulatory prospects [1][2]. Group 1: Allegations - The complaint alleges that during the class period from March 24, 2023, to May 14, 2025, Biohaven's statements regarding the regulatory prospects of its product candidate, troriluzole, were overstated [1]. - It is claimed that the efficacy and clinical prospects of BHV-7000 as a treatment for bipolar disorder were also overstated [1]. - The revelations of these overstated claims are likely to have a significant negative impact on Biohaven's business and financial condition [1]. Group 2: Class Action Details - Shareholders who purchased shares of BHVN during the specified class period are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for September 12, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflate stock prices [3].

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. and certain officers for alleged violations of federal securities laws during the Class Period from March 24, 2023, to May 14, 2025, seeking damages for affected investors [1][6]. Company Overview - Biohaven is a biopharmaceutical company focused on developing therapies in immunology, neuroscience, and oncology, with notable product candidates including troriluzole for spinocerebellar ataxia and BHV-7000 for bipolar disorder [3]. Regulatory Developments - In May 2022, a Phase 3 trial for troriluzole failed to meet its primary endpoint, yet the company continued to promote its regulatory prospects based on post-hoc analyses [4]. - Biohaven submitted a New Drug Application (NDA) for troriluzole to the FDA in May 2023, and the European Medicines Agency (EMA) accepted its Marketing Authorization Application (MAA) in October 2023 [5]. Allegations of Misleading Statements - Throughout the Class Period, Biohaven's executives allegedly made materially false and misleading statements regarding the company's business and the regulatory prospects of its products, particularly regarding troriluzole and BHV-7000 [6]. Stock Price Reactions - Following the FDA's rejection of the troriluzole NDA on July 27, 2023, Biohaven's stock price dropped by $5.38, or 22.61%, closing at $18.42 [7]. - On March 3, 2025, after disclosing disappointing data for BHV-7000, the stock fell by $5.12, or 13.77%, to $32.06 [9]. - Reports of the withdrawal of the troriluzole MAA led to a stock price decline of $3.56, or 15.21%, closing at $19.84 on April 25, 2025 [10]. - On May 14, 2025, the announcement of an extended review period for the troriluzole NDA resulted in a further stock price drop of $3.84, or 19.53%, to $15.82 [11].